IVY RX Review

IVY RX, PLLC is the traceable legal operator. Florida Division of Corporations record L23000117920 shows an active company with a current principal address at 111 NE 1st Street in Miami. The official contact page uses the same street address with an eighth-floor mailbox designation.

The About page names Silvia Mosher, MD, Rocio Reategui, MD, and Katy Ordonez, MD as advisory-board members. It does not say those physicians provide the patient-specific consultations sold through the site. Product pages instead refer generally to affiliated or licensed clinicians, and no current treating-clinician roster, state-license table, or assignment method is public.

The care flow starts with an online questionnaire. Current marketing says the form takes about five minutes and that a clinician may review it the same day or within twenty-four hours. The telehealth consent permits audio, video, or asynchronous communication. Public pages do not identify one required format for every product, and a prescription is not guaranteed.

The current weight-loss page lists a full-dose compounded GLP-1 program from $97 for four doses. The product page says the program may use tirzepatide or semaglutide, but does not show which ingredient, supply, plan term, or promotion produces $97. Because the amount cannot be assigned to one exact medication and commitment, it is not used as either drug's comparison price.

The microdose page similarly advertises compounded tirzepatide or semaglutide from $77 for four doses without assigning the amount to an ingredient, strength, concentration, quantity, term, or checkout condition. The product remains one ambiguous microdose program rather than two additional medication cards.

The Ozempic and Mounjaro pages each show $1,399. The Ozempic page identifies semaglutide, and the Mounjaro page identifies tirzepatide, but the surrounding copy is not reliable enough for direct brand comparison. The Mounjaro page tells readers how to take compounded GLP-1s, includes copied glutathione headings, and carries a disclaimer saying medications offered by IVY RX are not manufactured by the trademark owners. The draft therefore requires checkout confirmation of manufacturer, NDC, quantity, and pharmacy before treating either page as a verified brand supply.

Metformin is the clearest current weight-management bundle. The page shows $90 for three months and 180 tablets, while its title identifies metformin ER 500 mg. That bundle equals $30 per month, but it is not labeled Avg. because only one plan term is published. Patients should still confirm the prescribed daily dose and whether the 180 tablets are dispensed in one shipment or across refills.

NAD+ injection starts at $179 per month. The help center says the order includes one 5 mL vial at 200 mg/mL plus syringes and needles, although the same article first calls it 100 mg per vial. The product page does not publish a second comparable plan term, so the card uses the current one-term price and preserves the concentration conflict.

NAD+ nasal spray publishes four one-time, upfront terms: $279 for one month, $747 for three, $1,374 for six, and $2,388 for twelve. The plan-level monthly rates are $279, $249, $229, and $199. Their unweighted mean is $239, displayed as Avg. $239/mo. The page's separate from-$179 headline does not match the table and is not used in the average.

Glutathione injection starts at $179. The current help center identifies one 10 mL vial at 200 mg/mL, twenty doses, syringes, and needles. IVY RX does not publish a universal injection frequency or refill cadence, so $179 remains a per-order amount rather than a monthly price.

Methylcobalamin B12 injection is $179 per order. The site identifies a subcutaneous formulation and a 5 mL vial at 2,000 mcg/mL for ten injections with supplies. It does not publish one standard dosing cadence or refill interval, so no monthly equivalent is inferred.

Sermorelin publishes $225 for one month, $585 for three months, and $1,050 for six months, all paid upfront as a one-time purchase. The monthly rates are $225, $195, and $175, with an unweighted mean of $198.33 displayed as Avg. $198/mo. The page says subcutaneous dosing at bedtime five days per week or as directed, while the help center identifies 3 mg/mL.

The current supplement navigation lists BPC 157 at $129, Gut Peptide Complex at $89, Methylene Blue at $89, and GLP-1 Boost at $72. BPC 157 is a 500 mcg capsule, not an injection. Methylene Blue is a 15 mg capsule. Gut Peptide Complex and GLP-1 Boost are multi-ingredient supplements. They are discussed as products and not expanded into prescription therapy cards or ingredient-level price comparisons.

Older help-center articles discuss NAD+ cream, glutathione nasal spray, sublingual semaglutide, tretinoin plus niacinamide, erectile-dysfunction drugs, and finasteride. Those references are not enough to establish current availability because the treatments are absent from the reviewed main navigation and no current order path was verified. They do not create extra therapies in this review.

No partner pharmacy is named on the reviewed public pages. IVY RX says medications may be prepared by state-licensed pharmacies, shipped by an FDA-registered U.S. pharmacy, compounded by a 503A pharmacy, or sourced through pharmacies compliant with 503B and USP 797 standards. Registration is not FDA approval, and those descriptions do not identify the facility responsible for an individual prescription.

IVY RX also says products are independently tested in FDA- or FDA-and-DEA-registered laboratories and shows passed potency, sterility, endotoxin, and pH labels. No current certificate, lot number, laboratory name, test date, or patient-specific pharmacy is linked from the reviewed pages. The review attributes these claims to IVY RX and does not treat them as independent verification.

Compounded drugs are not FDA approved, and FDA does not verify their safety, effectiveness, or quality before marketing. FDA currently says semaglutide and tirzepatide are not on the drug-shortage list or 503B bulks list. Federal law restricts routine copies of commercially available products, while a documented patient-specific significant difference can matter under section 503A. IVY RX does not publish the assigned pharmacy or individual compounding basis, so the draft does not decide whether a specific prescription is lawful.

IVY RX does not accept public or private insurance. Its GLP-1 page says HSA and FSA reimbursement is available with an itemized receipt, but the account administrator controls eligibility. The help center also lists Affirm, Klarna, and Afterpay as possible checkout methods, with availability depending on product, location, and security checks.

Billing and cancellation language does not resolve cleanly. The contact page says there are no long-term contracts or cancellation fees. Weight-loss support says each monthly check-in must occur before billing and shipping and that an incomplete check-in cancels renewal with no automatic refill or charge. The older terms describe one- or three-month prepaid subscriptions with monthly auto-renewal, while current NAD+ nasal spray and sermorelin tables require a one-time upfront payment for longer terms.

Refund language also conflicts. The current refund page says returns are not accepted and invites the customer to seek a solution. The general FAQ says transactions are final and no reimbursements or prescription returns are available, apart from a dispensing error inquiry. The older terms describe a detailed refund request within fifteen days that IVY RX may deny. A customer should obtain the controlling outcome in writing before prepaying.

The shipping help center estimates three to five business days for pharmacy processing, or seven to ten during high demand, followed by free two-day shipping without a signature. Tracking is available by email and in the portal. Some product marketing promises delivery in as little as two days or pharmacy departure within twenty-four to forty-eight hours, so those faster statements are not treated as universal guarantees.

IVY RX advertises access to licensed professionals in all fifty states, but the exact product depends on clinician licensure, pharmacy reach, intake answers, and state restrictions. The review does not convert the broad platform statement into a guarantee that every formulation is available in every state.

Customer care is available by phone at 866-464-8979, email, and patient portal. The contact page lists Monday through Friday from 9 a.m. to 9 p.m. Eastern and Saturday and Sunday from 10 a.m. to 7 p.m. Eastern. It does not publish a separate guaranteed response time or adverse-event escalation standard.

The current privacy policy says IVY RX is not a HIPAA-covered entity and that health-related information submitted through its own website or service is not protected health information under HIPAA. It also describes IP, clickstream, mouse-movement, cookie, device, and advertising data collection, plus sharing of identifiers and internet activity for cross-context behavioral advertising. Treating providers and pharmacies may have separate HIPAA obligations.